BLOCKStrain Technology Corp. (TSXV:DNAX) (OTC:BKKSF) (“BLOCKStrain”), creator of the first Blockchain-secured, fully-integrated IP tracking platform for the cannabis industry, today announced it has appointed Dr. James LaValle as it Chief Medical Manager. In this new role, Dr. LaValle will provide leadership and direction with respect to scientific and medical aspects of the core software of the company, as well as areas of additional product and business development.

Dr. James LaValle has more than 40 years of experience in the natural products industry as a clinician, industry consultant and educator.  He has dedicated his professional career to becoming a voice for the emerging value of the natural product industry, with particular emphasis on the need for quality standards and transparency of ingredients in order to ensure consumer safety and efficacy.


“While Cannabidiol from hemp and cannabis products are taking the consumer and medical markets by storm, to date, this market segment has been fraught with quality and contamination issues that have tarnished the enormous value that these compounds can provide consumers. The BLOCKStrain technology represents a necessary evolution in ensuring product quality by tracking and reporting CBD and Cannabis ingredients starting from the soil all the way to the products on the store shelf”, stated Dr. LaValle. “The CBD/Cannabis industry must deliver quality finished goods to a level that inspires consumer confidence and provides them with safe products.  Verification of the level and type of active ingredients as well as absence of impurities should be simple, but the industry is riddled with inconsistent and in some cases dangerous final products.  I firmly believe BLOCKStrain has the potential to become a new standard for testing and reporting purity and content safety of not just cannabis, but other natural products as well.”

“Dr. LaValle’s immense expertise in the nutraceutical industry, and his dedication to ensuring high quality product standards is directly in line with BLOCKStrain’s mission of bringing transparency and integrity to the cannabis industry. With our technology, licensed producers, craft growers, other industry participants and most importantly patients and customers, can take affirmative action to ensure their products are as advertised.” said Robert Galarza, CEO of BLOCKStrain. “Dr. LaValle’s valued insight and well-established brand presence in the nutraceutical industry is unquestioned, and we are excited to have him as a key part of our growth strategy in cannabis and beyond.”

Dr. LaValle is the recipient of many prestigious awards. He was one of nine Americans chosen for the Inaugural Dietary Supplement Information Bureau Board, and was also awarded the Clinician of the Year Award from the Natural Products Association. He has authored 4 databases on natural products and teaches application of natural compounds in clinical practice to health care professionals around the world.  In addition, he has 35 years of clinical practice in integrative medicine.

In connection with this appointment BLOCKStrain has agreed to grant Dr. LaValle stock options to acquire up to 250,000 common shares in the capital of BLOCKStrain, subject to the terms of a stock option agreement to be entered into by the parties.

About BLOCKStrain:

BLOCKStrain has developed the first integrated blockchain platform to register and track intellectual property in the cannabis industry. BLOCKStrain’s technology allows cannabis growers and breeders to identify and secure rights to their intellectual property. It also streamlines the administrative process and reduces the costs of genetic and mandatory quality-control testing for legal cannabis. BLOCKStrain’s technology is proprietary, immutable and cryptographically secure, thereby establishing a single-source, accurate, validated, and permanent account for cannabis strains from ownership to market.

Forward-Looking Information:

The forward-looking information in this news release is based upon the expectations, estimates, projections, assumptions and views of future events which management believes to be reasonable in the circumstances. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking statements in this news release include statements regarding: the Chief Medical Manager’s anticipated role with BLOCKStrain and that his expertise will benefit BLOCKStrain; the statement with respect to the emerging value of the natural products industry, including compounds containing cannabidiol from hemp and cannabis; that BLOCKStrain technology has the potential to become a new standard for testing and reporting purity and content safety for cannabis and other natural products; and statements regarding the business of the Company. Forward-looking information necessarily involves known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; loss of markets; changes to the growth and size of the natural product industry; consumer acceptance and adoption of natural products, including compounds containing cannabidiol from hemp and cannabis as compared to other products; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally; the ability of BLOCKStrain to implement its business strategies; competition; and other risks. These forward-looking statements are made as of the date hereof and BLOCKStrain disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE .

For further information: BLOCKStrain Technology Corp. Robert Galarza, Chief Executive Officer and Director; Investor Inquiries: Crystal Quast Bullseye Corporate, 1-844-656-3629, Quast@BullseyeCorporate.com; Media Inquiries: Corey Herscu, 416-410-0404, corey@rnmkr.agency

Click here to connect with BLOCKStrain Technology Corp. (TSXV:DNAX) (OTC:BKKSF) for an Investor Presentation. 

Source: www.newswire.ca

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less

It’s been just over a year since recreational cannabis was legalised in the Australian Capital Territory (ACT), home to the nation’s capital city of Canberra.

Announced on September 25, 2019, and brought into effect on January 31, 2020, the rules make it legal to possess and personally use small amounts of cannabis.

Keep reading... Show less

Pac Roots Cannabis Corp. (CSE: PACR) (“PacRoots” or the “Company”), announces the closing of its previously announced non-brokered private placement (see press release dated January 25, 2021).

Aggregate gross proceeds of $1,340,685.90 were raised through the issuance of 7,448,255 units (each a “Unit”). Each Unit consists of one common shares and one share purchase warrant. Each warrant is exercisable at a price of $0.30 per share until February 23, 2024.

Keep reading... Show less

 Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States will release its fourth quarter 2020 financial results on Tuesday, March 23, 2021 before markets open. Following the earnings release, management will host a conference call at 8:30 AM Eastern Time to review the financial results.

All interested parties can join the conference call by dialing 1-888-231-8191 or 1-647-427-7450, conference ID: 7066881. Please dial in 15 minutes prior to the call to secure a line. The conference call will be archived for replay until March 30, 2021 . To access the archived conference call, please dial 1-855-859-2056 and enter the encore code 7066881.

Keep reading... Show less